

Richard Platt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3950836/publications.pdf>

Version: 2024-02-01

59
papers

3,601
citations

257450

24
h-index

182427

51
g-index

60
all docs

60
docs citations

60
times ranked

4279
citing authors

#	ARTICLE	IF	CITATIONS
1	When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 30-34.	4.7	6
2	When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 108-115.	4.7	14
3	When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 116-121.	4.7	4
4	Barriers to identifying residents with dementia for embedded pragmatic trials: A call to action. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 638-641.	2.6	2
5	Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. <i>JAMA Network Open</i> , 2022, 5, e2214321.	5.9	4
6	PCORnet® 2020: current state, accomplishments, and future directions. <i>Journal of Clinical Epidemiology</i> , 2021, 129, 60-67.	5.0	98
7	Is Learning Worth the Trouble? “Improving Health Care System Participation in Embedded Research. <i>New England Journal of Medicine</i> , 2021, 385, 5-7.	27.0	15
8	42. INSPIRE-ASP UTI Trial: A 59 Hospital Cluster Randomized Evaluation of Intelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection versus Routine Antibiotic Selection Practices for Patients with Urinary Tract Infection (UTI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S142-S143.	0.9	1
9	426. COVID-19 Infection Prevention Practices That Exceed CDC Guidance: Balancing Extra Caution Against Impediments to Care. <i>Open Forum Infectious Diseases</i> , 2021, 8, S313-S314.	0.9	0
10	4. 137 Hospital Cluster-Randomized Trial of Mupirocin-Chlorhexidine vs Iodophor-Chlorhexidine for Universal Decolonization in Intensive Care Units (ICUs) (Mupirocin Iodophor Swap Out Trial). <i>Open Forum Infectious Diseases</i> , 2021, 8, S3-S4.	0.9	4
11	171. The Impact of COVID-19 on Healthcare-Associated Infections. <i>Open Forum Infectious Diseases</i> , 2021, 8, S102-S103.	0.9	4
12	13. INSPIRE-ASP Pneumonia Trial: A 59 Hospital Cluster Randomized Evaluation of Intelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection versus Routine Antibiotic Selection Practices for Patients with Pneumonia. <i>Open Forum Infectious Diseases</i> , 2021, 8, S9-S10.	0.9	2
13	41. Assessing Past vs Present COVID-19 Infection: A Survey of Criteria for Discontinuing Precautions in Asymptomatic Patients. <i>Open Forum Infectious Diseases</i> , 2021, 8, S29-S31.	0.9	0
14	How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 3-7.	1.9	28
15	Considerations for using distributed research networks to conduct aspects of randomized trials. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100515.	1.1	5
16	University of Pennsylvania 12th annual conference on statistical issues in clinical trials: Electronic health records in randomized clinical trials—challenges and opportunities (morning panel session). <i>Clinical Trials</i> , 2020, 17, 405-413.	1.6	0
17	Using Healthcare Data in Embedded Pragmatic Clinical Trials among People Living with Dementia and Their Caregivers: <sc>State of the Art</sc>. <i>Journal of the American Geriatrics Society</i> , 2020, 68, S49-S54.	2.6	14
18	Rethinking ethical oversight in the era of the learning health system. <i>Healthcare</i> , 2020, 8, 100462.	1.3	7

#	ARTICLE	IF	CITATIONS
19	The Emergence of Population Health in US Academic Medicine. <i>JAMA Network Open</i> , 2019, 2, e192200.	5.9	23
20	Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory. <i>BMC Medical Research Methodology</i> , 2017, 17, 144.	3.1	127
21	Objective Sepsis Surveillance Using Electronic Clinical Data. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 163-171.	1.8	66
22	Using a Handheld Device for Patient Data Collection: A Pilot for Medical Countermeasures Surveillance. <i>Public Health Reports</i> , 2016, 131, 30-34.	2.5	3
23	Improving documentation and coding for acute organ dysfunction biases estimates of changing sepsis severity and burden: a retrospective study. <i>Critical Care</i> , 2015, 19, 338.	5.8	48
24	Neurotoxicity of Generic Anesthesia Agents in Infants and Children. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1515.	7.4	48
25	Potential Adverse Effects of Anesthesia in Children—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 409.	7.4	2
26	Comparison of Trends in Sepsis Incidence and Coding Using Administrative Claims Versus Objective Clinical Data. <i>Clinical Infectious Diseases</i> , 2015, 60, 88-95.	5.8	147
27	Launching PCORnet, a national patient-centered clinical research network. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 578-582.	4.4	491
28	Four Health Data Networks Illustrate The Potential For A Shared National Multipurpose Big-Data Network. <i>Health Affairs</i> , 2014, 33, 1178-1186.	5.2	106
29	Algorithms for identification of Guillain-Barré Syndrome among adolescents in claims databases. <i>Vaccine</i> , 2013, 31, 2075-2079.	3.8	19
30	Targeted versus Universal Decolonization to Prevent ICU Infection. <i>New England Journal of Medicine</i> , 2013, 368, 2255-2265.	27.0	676
31	The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 12-17.	1.9	51
32	The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1-8.	1.9	155
33	The U.S. Food and Drug Administration's Mini-Sentinel Program. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1-303.	1.9	156
34	Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1350-1358.	1.9	38
35	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. <i>Transfusion</i> , 2012, 52, 1363-1378.	1.6	11
36	Time for a Culture Change?. <i>New England Journal of Medicine</i> , 2011, 364, 1464-1465.	27.0	13

#	ARTICLE	IF	CITATIONS
37	Developing the Sentinel System – A National Resource for Evidence Development. <i>New England Journal of Medicine</i> , 2011, 364, 498-499.	27.0	308
38	Cluster Randomized Trials in Comparative Effectiveness Research. <i>Medical Care</i> , 2010, 48, S52-S57.	2.4	43
39	The New Sentinel Network – Improving the Evidence of Medical-Product Safety. <i>New England Journal of Medicine</i> , 2009, 361, 645-647.	27.0	203
40	Cluster randomized trials to study the comparative effectiveness of therapeutics: stakeholders' concerns and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 554-561.	1.9	15
41	Opportunity Knocks. <i>Epidemiology</i> , 2009, 20, 662-663.	2.7	7
42	Active drug safety surveillance: a tool to improve public health. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 1175-1182.	1.9	30
43	A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 1226-1234.	1.9	37
44	Comparing Drug Effectiveness at Health Plans: The Ethics of Cluster Randomized Trials. <i>Hastings Center Report</i> , 2008, 38, 39-48.	1.0	23
45	Improving Methicillin-Resistant <i>Staphylococcus aureus</i> Surveillance and Reporting in Intensive Care Units. <i>Journal of Infectious Diseases</i> , 2007, 195, 330-338.	4.0	100
46	Speed Bumps, Potholes, And Tollbooths On The Road To Panacea: Making Best Use Of Data. <i>Health Affairs</i> , 2007, 26, w153-w155.	5.2	4
47	Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events. <i>Medical Care</i> , 2007, 45, S89-S95.	2.4	195
48	Cluster Randomized Trials. <i>Medical Care</i> , 2007, 45, S29-S37.	2.4	29
49	Syndromic surveillance using minimum transfer of identifiable data: the example of the National Bioterrorism Syndromic Surveillance Demonstration Program. <i>Journal of Urban Health</i> , 2003, 80, i25-31.	3.6	29
50	Gastric and Duodenal Safety of Daily Alendronate. <i>Archives of Internal Medicine</i> , 2002, 162, 936.	3.8	53
51	Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , 2001, 10, 373-377.	1.9	78
52	Bayesian Inference on Protective Antibody Levels Using Case-Control Data. <i>Biometrics</i> , 2001, 57, 135-142.	1.4	18
53	Erythromycin Prolongs the QTc Interval Among Patients with Pneumonia. , 1997, 6, 13-19.		5
54	Surveillance for Surgical Site Infections: The Uses of Antibiotic Exposure. <i>Infection Control and Hospital Epidemiology</i> , 1994, 15, 717-723.	1.8	11

#	ARTICLE	IF	CITATIONS
55	Effect of federally mandated education policies on prescribing of isotretinoin to women of childbearing age. <i>Pharmacoepidemiology and Drug Safety</i> , 1993, 2, 217-221.	1.9	0
56	Confound It!. <i>Infection Control</i> , 1987, 8, 143-144.	0.1	4
57	Predictors of Response to Therapy for Infections Caused by <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 1984, 6, S759-S768.	5.8	1
58	Pharmacovigilance in the HMO Research Network. , 0, , 391-398.		2
59	The HMO Research Network. , 0, , 261-269.		6